On October 12, 2022 Perimeter Medical Imaging AI, Inc. (TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) – a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs – reported that two poster presentations at the Annual Meeting of the College of American Pathologists 2022 (CAP22), which took place October 8 to 11, 2022 in New Orleans, LA (Press release, Perimeter Medical Imaging AI, OCT 12, 2022, View Source [SID1234621973]). The research presented validates the potential use of Perimeter S-Series OCT to intraoperatively image specimens across a variety of tissue types, such as breast, thyroid, kidney, liver, lung, colon, heart, pancreas, spleen, and adrenal glands:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Validation of Wide-Field Optical Coherence Tomography for Microstructural Analysis of Tissue From Multiple Organs (Poster No. 108)
Intraoperative Use of Wide-Field Optical Coherence Tomography to Evaluate Tissue Microstructure in the Oral Cavity and Oropharynx (Poster No. 170)
Andrew Berkeley, Perimeter’s Co-founder stated, "We were excited to present to leading pathologists at CAP22 with data that support the potential use of Perimeter’s OCT medical imaging technology across several tissue types, including the analysis of margins in head and neck surgery. This research helps demonstrate that Perimeter S-Series has the potential to be used in a variety of settings to help ‘bridge the gap’ between the surgeon’s need for immediate ‘real time’ info in the operating room with images that correlate to histological results, with a process that does not interfere with surgical procedures or final pathology."

On October 12, 2022 CANbridge Pharmaceuticals, Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies to treat rare diseases and oncology, reported that it will take part in two upcoming investor conferences (Press release, CANbridge Life Sciences, OCT 12, 2022, View Source [SID1234621972]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Jefferies London Healthcare Conference, November 15-17
The Morgan Stanley 21st Annual Asia Pacific Summit, Singapore, November 16-18
The company’s presentation will be available on the website in the Investor section.

In addition, the company announced that data from a pre-clinical development program in collaboration with UMass Chan Medical School will be presented at:

The ESGCT 29th Congress, in Edinburgh, Scotland, October 13, 3:30 PM BST

Title: Endogenous Human SMN1 Promoter-driven Gene Replacement Improves the Efficacy and Safety of AAV9-mediated Gene Therapy for Spinal Muscular Atrophy in Mice

Type: Oral presentation
Presenter: Guangping Gao, Ph.D., Co-Director, Li Weibo Institute for Rare Diseases Research, Director, the Horae Gene Therapy Center and Viral Vector Core, Professor of Microbiology and Physiological Systems and Penelope Booth Rockwell Professor in Biomedical Research at UMass Chan Medical School

On October 12, 2022 ZAP Surgical Systems, Inc. reported that the University Hospital in Olsztyn, in collaboration with the University of Warmia and Mazury in Olsztyn, will become the first center in Poland and Eastern Europe to offer completely non-invasive brain tumor treatments with the ZAP-X Gyroscopic Radiosurgery platform (Press release, ZAP Surgical Systems, OCT 12, 2022, View Source [SID1234621971]). System installation has commenced, and first patient treatments are planned to begin in early 2023.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As a completely non-invasive outpatient treatment for select brain tumors and metastatic disease, stereotactic radiosurgery (SRS) is a proven alternative to historical surgical procedures. Unlike surgery however, the SRS procedure requires no incisions and is painless. In most cases patients immediately return to normal activities following SRS.

The recently unveiled ZAP-X radiosurgery system is renowned for its unique use of two axes of motion to direct radiation beams from hundreds of unique angles. This maneuverability allows clinicians to lower incidental radiation exposure to the brain and nearby organs at-risk, thus aiming to lower the potential for patient complications.

"To protect the healthy brain and preserve patient cognitive function, cranial radiosurgery requires exacting precision beyond that which is typical of conventional radiotherapy of the body," says Prof. Dr. Sergiusz Nawrocki, Head of the Department of Oncology and Radiotherapy Clinic at the University of Warmia and Mazury in Olsztyn, and Head of the University Medical College. "From the gyroscopic dual axes design, down to the smallest details, everything about ZAP-X is purpose-built for SRS, and will allow us to better focus high-intensity radiation on tumors while strictly controlling potential radiation exposure of critical structures such as the eyes and brain stem."

The ZAP-X system is the latest advance in surgical robotics and first new dedicated cranial radiosurgery platform in nearly half a century. Prior to ZAP-X, state-of-the-art SRS often required hospitals to house large quantities of costly and dangerous Cobalt-60 for radiosurgery beam generation. ZAP-X eliminates this requirement by using leading-edge linear accelerator technology.

ZAP-X is also the first and only radiation delivery system to eliminate the need for 2-3-million-pound concrete radiation treatment vaults, thereby allowing for exterior treatment suite windows for the first time ever. This breakthrough not only creates a more comfortable patient experience, but also brings world-class SRS to communities previously considered infeasible by significantly reducing healthcare system costs.

On October 12, 2022 Calidi Biotherapeutics, Inc. (Calidi), a clinical-stage biotechnology company that is pioneering allogeneic cell-based platforms to revolutionize oncolytic virus therapies, reported a poster presentation highlighting pre-clinical data from the company’s SuperNova1 (SNV1) program at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting, taking place in Boston, Massachusetts and virtually, November 8-12, 2022 (Press release, Calidi Biotherapeutics, OCT 12, 2022, View Source [SID1234621970]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the poster presentation are below:

Title: SuperNova1 (SNV1), a novel oncolytic-cell based platform for cancer therapy
Abstract ID: 1137
Location: Poster Hall C
Date: November 10, 2022, 9:00 a.m. – 9:00 p.m. ET
Presenters: Duong H. Nguyen, Ph.D., Director of Translational Research and Innovation, and Antonio F. Santidrian, Ph.D., Senior Vice President, Global Head of Research and Development

On October 12, 2022 Scorpion Therapeutics, Inc. ("Scorpion"), a pioneering oncology company redefining the frontier of precision medicine, reported that it will present preclinical proof-of-concept data for STX-721 in a poster session at the European Organisation for Research and Treatment of Cancer, the National Cancer Institute, and the American Association for Cancer Research (AACR) (Free AACR Whitepaper) ("EORTC-NCI-AACR") Symposium 2022 in Barcelona, Spain, taking place October 26 – 28, 2022 (Press release, Scorpion Therapeutics, OCT 12, 2022, View Source [SID1234621969]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

STX-721 (formerly ST-5924) is Scorpion’s next-generation, orally delivered, small molecule designed with potential best-in-class selectivity for exon 20 insertion mutations in epidermal growth factor receptors ("EGFR"), a well-known, clinically validated oncogenic driver in non-small cell lung cancer ("NSCLC"). STX-721 is progressing through preclinical studies and Scorpion expects to submit an IND application to the U.S. Food and Drug Administration in 2023.

"We are excited to share foundational proof-of-concept data for STX-721, our next-generation EGFR inhibitor, which supports its potentially best-in-class product profile," said Axel Hoos, M.D., Ph.D., Chief Executive Officer of Scorpion Therapeutics. "The Scorpion team developed this small molecule with the goal of delivering superior selectivity, as well as improved safety, tolerability and efficacy compared to currently marketed EGFR Exon 20 therapies and other drug candidates in development. We believe STX-721 could meaningfully improve the treatment of people living with EGFR exon 20-mutant NSCLC and look forward to advancing into clinical studies next year."